Autosomal Dominant Optic Atrophy

Autosomal Dominant Optic Atrophy (ADOA) is a genetic eye condition that causes a slow, gradual loss of vision. It is the most common inherited disorder affecting the optic nerve, which is the cable that sends visual information from the eye to the brain. The condition usually begins in childhood, often before the age of 10, but the vision changes happen so slowly that many people don't notice exactly when they started. In ADOA, the cells in the eye that connect to the optic nerve slowly stop working and die off. This leads to a fading or "blind spot" in the center of a person's vision, making it harder to read, recognize faces, or see fine details. It also frequently affects color vision, making it difficult to tell the difference between shades of blue and green. Both eyes are usually affected equally. The severity of vision loss can vary a lot, even among family members with the same condition; some people have only mild vision problems, while others may experience more significant sight loss, though complete blindness is rare. Currently, there is no cure for ADOA, but regular eye exams are important to monitor the condition and provide low-vision aids like magnifiers if needed. Researchers are actively studying the disease, and new treatments, including gene therapies designed to help the optic nerve cells survive and function better, are currently being tested in clinical trials.

Condition category: Optic Neuropathy

Prevalence: 1 in 30,000 to 1 in 50,000

Inheritance patterns: Autosomal Dominant

Age of onset: First or second decade of life

Clinical overview: Autosomal Dominant Optic Atrophy (ADOA), also known as Kjer type optic atrophy, is the most common hereditary optic neuropathy. It is characterized by the insidious onset of bilateral, relatively symmetric visual impairment, typically beginning in the first or second decade of life. The clinical hallmark of the disease is the progressive degeneration of retinal ganglion cells, particularly within the papillomacular bundle, leading to ascending optic nerve atrophy. Clinically, patients present with a triad of signs: reduced visual acuity, visual field defects (most commonly central, centrocecal, or paracentral scotomas), and color vision deficiencies, classically described as tritanopia (blue-yellow axis defect), though red-green defects can also occur. Funduscopic examination typically reveals temporal pallor of the optic disc, often accompanied by a temporal gray crescent and sometimes abnormal optic disc cupping. The severity of visual loss is highly variable, ranging from mild to severe, with visual acuity typically between 20/80 and 20/120, though legal blindness is uncommon. While the classic form of ADOA is an isolated optic neuropathy, approximately 20% of patients with OPA1 mutations develop "ADOA plus" phenotypes. These syndromic forms present with additional extra-ocular manifestations that typically emerge in early adulthood, including sensorineural hearing loss, peripheral neuropathy, myopathy, ataxia, and chronic progressive external ophthalmoplegia (CPEO). The disease exhibits incomplete penetrance and significant intrafamilial and interfamilial phenotypic variability.

Patient and family guide: Autosomal Dominant Optic Atrophy (ADOA) is a genetic eye condition that causes a slow, gradual loss of vision. It is the most common inherited disorder affecting the optic nerve, which is the cable that sends visual information from the eye to the brain. The condition usually begins in childhood, often before the age of 10, but the vision changes happen so slowly that many people don't notice exactly when they started. In ADOA, the cells in the eye that connect to the optic nerve slowly stop working and die off. This leads to a fading or "blind spot" in the center of a person's vision, making it harder to read, recognize faces, or see fine details. It also frequently affects color vision, making it difficult to tell the difference between shades of blue and green. Both eyes are usually affected equally. The severity of vision loss can vary a lot, even among family members with the same condition; some people have only mild vision problems, while others may experience more significant sight loss, though complete blindness is rare. Currently, there is no cure for ADOA, but regular eye exams are important to monitor the condition and provide low-vision aids like magnifiers if needed. Researchers are actively studying the disease, and new treatments, including gene therapies designed to help the optic nerve cells survive and function better, are currently being tested in clinical trials.

Symptoms and clinical features: Symptoms typically begin in the first or second decade of life with a slow, insidious onset of bilateral vision loss. Patients experience a gradual decrease in central visual acuity, which may range from mild to severe. A prominent symptom is the development of central, centrocecal, or paracentral blind spots (scotomas) in the visual field. Color vision is frequently impaired, most commonly affecting the ability to distinguish blue and yellow (tritanopia). The progression of symptoms is very slow, and there is significant variability in symptom severity even among affected members of the same family.

Molecular pathology: Autosomal Dominant Optic Atrophy is primarily caused by mutations in the OPA1 gene, located on chromosome 3q28-q29, which accounts for the majority of cases. The OPA1 gene encodes a dynamin-related GTPase protein that localizes to the inner mitochondrial membrane. This protein is essential for mitochondrial dynamics, specifically mitochondrial fusion, cristae organization, and the maintenance of mitochondrial DNA (mtDNA). It also plays a crucial role in oxidative phosphorylation and the regulation of apoptosis. Mutations in OPA1 lead to haploinsufficiency, resulting in a 50% reduction in functional OPA1 protein. This deficiency disrupts mitochondrial network dynamics, causing mitochondria to become fragmented and disorganized. The impaired mitochondrial function leads to a decrease in ATP production via oxidative phosphorylation and an increase in reactive oxygen species (ROS). Retinal ganglion cells (RGCs), particularly those in the papillomacular bundle, have high energy demands and are highly sensitive to mitochondrial dysfunction. The metabolic stress and increased ROS levels trigger premature apoptosis of these RGCs. The progressive loss of RGCs and the subsequent degeneration of their axons, which form the optic nerve, result in the characteristic optic atrophy and visual impairment seen in the disease.

Genetics: Autosomal Dominant Optic Atrophy is inherited in an autosomal dominant pattern, meaning a single copy of the mutated gene is sufficient to cause the disorder. Most cases are inherited from an affected parent, though de novo mutations can occur in individuals with no family history. The condition exhibits incomplete penetrance and highly variable expressivity, meaning the severity of vision loss can vary significantly even among affected members of the same family. Some individuals with the mutation may remain asymptomatic or have very mild, subclinical signs. Genetic counseling is recommended for affected individuals and their families. Because of the autosomal dominant inheritance, each child of an affected individual has a 50% chance of inheriting the mutated gene. However, due to incomplete penetrance and variable expressivity, predicting the exact age of onset or severity of vision loss in offspring is challenging. Prenatal testing is possible for families with a known mutation, but it cannot predict the clinical outcome.

Diagnostic evaluation: Diagnosis is based on clinical presentation of bilateral, symmetric, and slowly progressive vision loss starting in childhood. Key findings include temporal or diffuse optic disc pallor on fundus examination, central or centrocecal scotomas on visual field testing, and color vision deficits (often tritanopia). Optical coherence tomography (OCT) shows thinning of the retinal nerve fiber layer, particularly in the temporal quadrant. Visual evoked potentials (VEP) reveal delayed latencies and reduced amplitudes, while pattern electroretinograms show a reduced N95 component. Genetic testing confirming a mutation in the OPA1 gene (or less commonly other OPA genes) establishes the definitive diagnosis. Family history is supportive but may be absent due to variable expressivity and incomplete penetrance.

Differential diagnosis: Leber Hereditary Optic Neuropathy (LHON), Nutritional Amblyopia, Toxic Optic Neuropathy, Demyelinative disease, Ocular dysthyroidism, Macular Dystrophies, Glaucoma, Wolfram syndrome

Natural history: The disease typically presents insidiously in the first or second decade of life with mild, bilateral vision loss. Because the progression is very slow and gradual, many patients cannot pinpoint the exact onset of their symptoms. Vision loss progresses steadily over time, though the rate of decline varies widely among individuals. While some patients maintain relatively good vision throughout their lives, others may experience more significant deterioration, particularly later in life. Spontaneous recovery of vision is exceptionally rare. In a subset of patients (ADOA plus), additional neurological symptoms such as hearing loss or myopathy may develop in early adulthood.

Management and treatment research: ### Current management and supportive care There is currently no cure or approved treatment proven to slow or reverse vision loss from autosomal dominant optic atrophy (ADOA). Care focuses on monitoring vision, supporting daily activities, and addressing the effects of reduced central and color vision. Management may include: - Regular follow-up with an ophthalmologist or neuro-ophthalmologist. Assessments may include visual-acuity testing, color-vision testing, visual-field testing, and optical coherence tomography (OCT), an imaging test that measures layers of the retina and optic nerve. - Genetic testing and genetic counseling, particularly for changes in the **OPA1** gene, the most common genetic cause of ADOA. A confirmed genetic diagnosis can clarify inheritance patterns and may help identify relevant research studies. - Low-vision rehabilitation, including magnifiers, electronic reading aids, screen magnification or speech software, lighting adjustments, orientation and mobility services, and school or workplace accommodations. - Avoiding tobacco and limiting excessive alcohol use, as these may add stress to mitochondrial function. Mitochondria are the parts of cells that produce energy and are affected in many people with OPA1-associated ADOA. - Discussing any medicines, vitamins, or supplements with the clinical team. Supplements such as coenzyme Q10, idebenone, and vitamins are sometimes used, but their benefits for ADOA have not been established in clinical trials. ### Approved therapies No therapies are currently approved specifically to treat or slow vision loss caused by ADOA. ### Investigational therapies #### PYC-001 PYC-001 is an investigational treatment being studied in people with **OPA1** mutation-associated ADOA. Its safety and potential effects on vision are not yet known. - **NCT06461286 (Sundew):** A Phase 1 study evaluating a single intravitreal (into-the-eye) dose of PYC-001. This study is active but not recruiting. - **NCT06970106 (Myrtle):** A recruiting Phase 1/2 study evaluating the safety of single and repeat intravitreal PYC-001 injections in people with ADOA. Early-phase clinical trials primarily evaluate safety, tolerability, and dose. They are not designed to establish that a treatment improves or preserves vision. #### Nicotinamide Nicotinamide, also called vitamin B3, is being studied in OPA1-associated dominant optic atrophy. It has roles in cellular energy processes, including pathways relevant to mitochondrial health. - **NCT06007391:** A Phase 2/3 study evaluating the tolerance and effectiveness of nicotinamide in people with OPA1-associated dominant optic atrophy. This study is active but not recruiting. Nicotinamide is not a proven treatment for ADOA outside of research. #### Natural-history research Natural-history studies follow people over time to better understand how a condition changes, including differences in vision loss between individuals. These studies can help identify useful outcome measures for future treatment trials. - **NCT07729982:** A recruiting longitudinal natural-history study of OPA1-associated ADOA. ### Considering clinical trial participation Clinical trials may offer an opportunity to contribute to research and, in some cases, receive an investigational treatment. However, potential benefits are uncertain, and studies may involve risks, eye injections, frequent visits, testing, and specific eligibility requirements. A treating eye specialist or genetic counselor can help review whether a study may be appropriate. Trial recruitment status and eligibility criteria can change over time.

Outlook: The visual prognosis for Autosomal Dominant Optic Atrophy is generally better than for other hereditary optic neuropathies like LHON. Vision loss is typically mild to moderate, and more than 80% of patients maintain visual acuity better than 20/200. Legal blindness is rare. The condition does not affect intellectual development or lifespan. While the visual impairment is irreversible and slowly progressive, most patients can lead normal familial and social lives, though vocational choices may be influenced by the degree of visual deficit.

Epidemiology: Autosomal Dominant Optic Atrophy is the most common hereditary optic neuropathy. It has an estimated worldwide prevalence of 1 in 30,000 to 1 in 50,000. The condition is notably more common in Denmark, where a founder effect results in a prevalence of approximately 1 in 10,000. It affects both males and females equally. Onset typically occurs in the first or second decade of life, often detected during routine school vision screenings, though later onset is possible.

Selected references: 1. Kjer B, Eiberg H, Kjer P, Rosenberg T. Dominant optic atrophy mapped to chromosome 3q region. II. Clinical and epidemiological aspects. Acta Ophthalmol Scand. 1996. 2. Newman NJ. Hereditary Optic Neuropathies: from the mitochondria to the optic nerve. Am J Ophthalmol. 2005. 3. Delettre C, Lenaers G, Pelloquin L, Belenguer P, Hamel CP. OPA1 (Kjer type) dominant optic atrophy: a novel mitochondrial disease. Mol Genet Metab. 2002. 4. Yu-Wai-Man P, Griffiths PG, Burke A, Sellar PW, Clarke MP, Gnanaraj L, Ah-Kine D, Hudson G, Czermin B, Taylor RW, Horvath R, Chinnery PF. The prevalence and natural history of dominant optic atrophy due to OPA1 mutations. Ophthalmology. 2010. 5. Cohn AC, Toomes C, Potter C, Towns KV, Hewitt AW, Inglehearn CF et al. Autosomal dominant optic atrophy: penetrance and expressivity in patients with OPA1 mutations. Am J Ophthalmol. 2007.